Overactive bladder: Drug therapy versus nerve stimulation

Nature Clinical Practice Urology

Volumn 2, Issue 7, 2005, Pages 310-311

  Pathak, Apurba S ^a   Aboseif, Sherif R ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; NEW DRUG; OXYBUTYNIN; PLACEBO; TOLTERODINE;

BEHAVIOR MODIFICATION; BLADDER CONTRACTION; BLEEDING; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DETRUSOR DYSSYNERGIA; DROWSINESS; DRUG COST; DRUG PENETRATION; DRUG WITHDRAWAL; DRY EYE; HUMAN; INFECTIOUS COMPLICATION; INTERMETHOD COMPARISON; NERVE STIMULATION; NEUROLOGIC DISEASE; NOCTURIA; OPTIMAL DRUG DOSE; OVERACTIVE BLADDER; PAIN; PATIENT COMPLIANCE; POLYURIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; URGE INCONTINENCE; URINARY DIVERSION; URINARY DYSFUNCTION; URINARY URGENCY; VISUAL IMPAIRMENT; XEROSTOMIA;

ELECTRIC STIMULATION; HUMANS; MUSCARINIC ANTAGONISTS; URINARY INCONTINENCE;

EID: 23744517370     PISSN: 17434270     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpuro0227     Document Type: Review

References (12)

1. Abrams P et al. (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21: 167-178
2. Chapple CR et al. (2002) Muscarinic receptor subtypes and management of the overactive bladder. Urology 60 (Suppl 1): 82-89
3. Andersson KE and Yoshida M (2003) Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur Urol 43: 1-5
4. Igawa Y (2000) Discussion: functional role of M(1), M(2), and M(3) muscarinic receptors in overactive bladder. Urology 55 (Suppl A): 47-49
5. Choppin A and Eglen RM (2001) Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br J Pharmacol 132: 835-842
6. Lai H et al. (2002) Selecting a medical therapy for overactive bladder. Reviews in Urology 4 (Suppl 4): S28-S37
7. Yarker YE et al. (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6: 243-262
8. Abrams P et al. (1998) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81: 801-810
9. Tanagho EA et al. (1989) Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. J Urol 142 (Pt 1): 340-345
10. Hassouna MM et al. (2000) Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 163: 1849-1854
11. Chartier-Kastler EJ et al. (2000) Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 164: 1476-1480
12. Aboseif S et al. (2002) Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. Urology 60: 52-56